Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bethge, W.
Right arrow Articles by Hebart, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bethge, W.
Right arrow Articles by Hebart, H
Haematologica, Vol 90, Issue Suppl, ECR22-ECR22
Copyright © 2005 by Ferrata Storti Foundation


Journal Article

Mucormycoses in patients with hematologic malignancies: an emerging fungal infection

WA Bethge, M Schmalzing, G Stuhler, U Schumacher, SM Krober, M Horger, H Einsele, L Kanz, and H Hebart

Medical Center University of Tubingen, Hematology/Oncology Otfried-Muller Str. 10 , 72076 Tubingen; Germany. wolfgang.bethge@med.uni-tuebingen.de

BACKGROUND AND OBJECTIVES: Mucormycoses are seen with an increasing incidence in immunocompromised patients. Most common presentations are rhinocerebral and pulmonary. We here report the experience of a single center with mucormycoses in patients with hematologic malignancies. RESULTS: Mucormycoses were diagnosed in six patients, (median age of 52 years; range, 26-74) treated between 2001-2004. Diagnoses included acute myeloid leukemia (AML) (n=3), acute lymphoblastic leukemia (n=1), chronic lymphocytic leukemia (n=1) and multiple myeloma (n=1). Mucormycosis was diagnosed in the neutropenic state following allogeneic hematopoietic cell transplantation (n=3) or intense chemotherapy (n=3). Sites of infections were rhinocerebral, facial and pulmonary involvement in one patient each and disseminated mucormycosis in three patients. The diagnosis was established by computed tomography followed by surgical interventions and histological diagnosis in 4 patients and post-mortem in two patients. Species identified were Rhizopus (n=3), Rhizomucor (n=2) and Absidia (n=1). Treatment responses were best if surgical resection was followed by aggressive antifungal chemotherapy. Five of six 6 patients died, all of complications of mucormycosis or their underlying disease. Only one patient with facial mucormycosis is still alive. CONCLUSIONS: This experience demonstrates that patient with mucormycoses have a high mortality rate and early recognition followed by aggressive surgical debridement, high dose antifungal therapy and attempts to correct the underlying immunocompromised state are crucial in the treatment of this fatal infection.


This article has been cited by other articles:


Home page
J. Clin. Microbiol.Home page
B. Spiess, W. Seifarth, M. Hummel, O. Frank, A. Fabarius, C. Zheng, H. Morz, R. Hehlmann, and D. Buchheidt
DNA Microarray-Based Detection and Identification of Fungal Pathogens in Clinical Samples from Neutropenic Patients
J. Clin. Microbiol., November 1, 2007; 45(11): 3743 - 3753.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2005 by the Ferrata Storti Foundation.